Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma
The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...
Drug
AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...
Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is...
GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...
BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...
Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...
Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...